Op-Ed Defends Relationships Between Pharmaceutical Companies, Researchers

Main Category: Pharma Industry / Biotech Industry
Article Date: 13 Apr 2009 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 stars

4 (2 votes)

Healthcare Prof:5 stars

5 (1 votes)


Critics who label relationships between university researchers and medical companies "as a morality play in which noble academics struggle to resist the dark, corrupting influence of industry" fail to realize that the "goal of medical research is not to publish papers, but to develop new treatments for people suffering from disease," management consultant David Shaywitz and Harvard University professor and Manhattan Institute Fellow Thomas Stossel write in a Wall Street Journal opinion piece. They continue, "After years of extensive public investment of billions of dollars in medical research, we have generated thousands of scientific papers, but few important new treatments for dreadful conditions."

They add that while "we have won some important battles" -- such as developments in statins and blood pressure medicines and HIV treatments -- "behind these spectacular achievements is an arduous, expensive and underappreciated journey, occurring largely in industry." The piece continues, "Given the vital role of medical products companies and the magnitude of their challenges, one might imagine that this industry would be admired," but "this enlightened view of industry is not widespread," as a "coterie of prominent critics we have previously dubbed as 'pharmascolds' ... routinely vilify the medical products industry and portray academics working with it as traitors and sellouts."

Shaywitz and Stossel write, "For the sake of the many patients whose diseases require innovative treatments -- and for the medical philanthropists determined to make it happen -- it's time for the leaders of the medical products industry to take pride in their purpose and start fighting back" (Shaywitz/Stossel, Wall Street Journal, 4/8).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Op-Ed Defends Relationships Between Pharmaceutical Companies, Researchers." Medical News Today. MediLexicon, Intl., 13 Apr. 2009. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/145800.php>

APA
Kaiser. (2009, April 13). "Op-Ed Defends Relationships Between Pharmaceutical Companies, Researchers." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/145800.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »